Aristotle Capital Management Portfolio holdings
AUM
$51.9B
This Quarter Return
+8.77%
1 Year Return
+11.53%
3 Year Return
+52.48%
5 Year Return
+110.4%
10 Year Return
+262.93%
AUM
$6.29B
AUM Growth
+$6.29B
(+26%)
Cap. Flow
+$887M
Cap. Flow
% of AUM
14.1%
Top 10 Holdings %
Top 10 Hldgs %
28.63%
Holding
141
New
7
Increased
81
Reduced
15
Closed
6
Top Buys
| 1 |
Oshkosh
OSK
|
$128M |
| 2 |
Banco Santander
SAN
|
$54.2M |
| 3 |
AbbVie
ABBV
|
$38.8M |
| 4 |
Diageo
DEO
|
$32.1M |
| 5 |
UN
Unilever NV New York Registry Shares
UN
|
$28.6M |
Top Sells
| 1 |
Bunge Global
BG
|
$101M |
| 2 |
Vodafone
VOD
|
$88.1M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$6.96M |
| 4 |
Lumen
LUMN
|
$6.42M |
| 5 |
Willis Towers Watson
WTW
|
$3.66M |
Sector Composition
| 1 | Financials | 15.87% |
| 2 | Technology | 13.73% |
| 3 | Consumer Discretionary | 12.95% |
| 4 | Healthcare | 11.99% |
| 5 | Industrials | 11.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
GSK
GSK
$79.3B
| $292K | ﹤0.01% |
5,462
| – | – |
|
|
ROSE
127
DELISTED
ROSETTA RESOURCES INC
ROSE
| $288K | ﹤0.01% |
6,000
| – | – |
|
128
Becton Dickinson
BDX
$54.3B
| $276K | ﹤0.01% |
+2,500
| New | +$276K |
|
|
POT
129
DELISTED
Potash Corp Of Saskatchewan
POT
| $261K | ﹤0.01% |
+7,930
| New | +$261K |
|
130
Air Products & Chemicals
APD
$64.8B
| $257K | ﹤0.01% |
+2,300
| New | +$257K |
|
131
Costco
COST
$421B
| $233K | ﹤0.01% |
1,955
-1,000
| -34% | -$119K |
|
132
Gilead Sciences
GILD
$140B
| $227K | ﹤0.01% |
+3,025
| New | +$227K |
|
133
AT&T
T
$208B
| $221K | ﹤0.01% |
6,275
| – | – |
|
|
MJN
134
DELISTED
Mead Johnson Nutrition Company
MJN
| $216K | ﹤0.01% |
+2,584
| New | +$216K |
|
135
Western Union
WU
$2.82B
| $173K | ﹤0.01% |
10,000
| – | – |
|
|
MNK
136
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – |
-157,903
| Closed | -$6.96M |
|
|
137
Willis Towers Watson
WTW
$31.9B
| – | – |
-84,519
| Closed | -$3.66M |
|
|
138
Vodafone
VOD
$28.2B
| – | – |
-2,503,369
| Closed | -$88.1M |
|
139
Teva Pharmaceuticals
TEVA
$21.5B
| – | – |
-88,268
| Closed | -$3.34M |
|
140
Nike
NKE
$110B
| – | – |
-5,200
| Closed | -$378K |
|
|
141
Lumen
LUMN
$4.84B
| – | – |
-204,700
| Closed | -$6.42M |
|